HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.

AbstractINTRODUCTION:
AZD6244 (ARRY-142886) is a potent, selective MEK inhibitor. This study aimed to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second- or third-line treatment in patients with advanced non-small cell lung cancer (NSCLC).
METHODS:
In this randomized phase II study, patients received either 100 mg oral AZD6244 free-base suspension twice daily or 500 mg/m(2) intravenous pemetrexed once every 3 weeks after pretreatment with a corticosteroid, folic acid, and vitamin B12. The primary end point of the study was the disease progression event count.
RESULTS:
Eighty-four patients were randomized. Disease progression events were experienced by 28 (70%) and 26 (59%) patients in the AZD6244 and pemetrexed groups, respectively. Median progression-free survival was not statistically significantly different between the AZD6244 and pemetrexed groups (67 versus 90 days, respectively; hazard ratio 1.08, two-sided 80% confidence interval = 0.75-1.54; p = 0.79). Two patients in the AZD6244 group had a best response to treatment of partial response. In the pemetrexed group, one patient achieved a complete response and one patient a partial response. Dermatitis acneiform, diarrhea, nausea, and vomiting were the most frequently reported adverse events with AZD6244, compared with fatigue, anemia, nausea, anorexia, and dermatitis acneiform with pemetrexed.
CONCLUSIONS:
Oral AZD6244 showed clinical activity as second- or third-line therapy for patients with advanced NSCLC. In an unselected NSCLC population, there is no suggestion that AZD6244 monotherapy offers any advantage over standard treatment with pemetrexed. Based on preclinical data and recent clinical observations, further development of AZD6244 in NSCLC should focus on BRAF or RAS mutation-positive patients and/or AZD6244-based combination regimens.
AuthorsJohn D Hainsworth, Cristina L Cebotaru, Vladimir Kanarev, Tudor E Ciuleanu, Danail Damyanov, Phillip Stella, Hristo Ganchev, Gillian Pover, Clive Morris, Valentina Tzekova
JournalJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 5 Issue 10 Pg. 1630-6 (Oct 2010) ISSN: 1556-1380 [Electronic] United States
PMID20802351 (Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • AZD 6244
  • Antimetabolites, Antineoplastic
  • Benzimidazoles
  • Glutamates
  • Pemetrexed
  • Guanine
Topics
  • Adenocarcinoma (drug therapy, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Benzimidazoles (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Cohort Studies
  • Female
  • Glutamates (therapeutic use)
  • Guanine (analogs & derivatives, therapeutic use)
  • Humans
  • Lung Neoplasms (drug therapy, pathology)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pemetrexed
  • Safety
  • Salvage Therapy
  • Survival Rate
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: